IL1A and myocardial infarction: A wide range of cardiovascular and metabolic disorders including gout, post-myocardial infarction remodeling, cerebrovascular accident, diabetes mellitus, and metabolic syndrome may profit from IL-1 inhibiting therapies as well (78).